| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 13
| Issue : 3 | Page : 150-153 |
|
|
An analysis of proposed etiological factors for sudden spike in mucormycosis infection during COVID-19 pandemic at a tertiary hospital of North India
Akhil Pratap Singh1, Prabhat Agrawal2, Vikas Kumar3
1 Department of Ent, S N Medical College, Agra, Uttar Pradesh, India
2 Department of Medicine, S N Medical College, Agra, Uttar Pradesh, India
3 Department of Microbiology, S N Medical College, Agra, Uttar Pradesh, India
Correspondence Address:
Dr. Akhil Pratap Singh
Department of Ent, S N Medical College, Agra, Uttar Pradesh
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/injms.injms_15_22
|
|
|
Aim: The aim is to analyze various possible etiological factors for the sudden outbreak of mucormycosis. Methods: A prospective observational study involving consecutive individuals with proven mucormycosis was undertaken at a tertiary care teaching hospital in North India from May 2021 to July 2021. A total of 88 patients with mucormycosis were studied for the demographic profile, COVID-19 status, various risk factors, COVID-19 immunization status, clinical staging of disease, and outcome of patients. Results: Out of 88 patients, 54 (61%) were males and 34 (39%) were females. The mean age of male patients was 50.5 ± 13.8 and female patients was 52.1 ± 14.1. Most of the patients were in stage two, i.e., 45 (51.1%) and 26 (29.5%) in stage three of the disease. Past history of diabetes was present in 49 (55%) patients. Forty-one (46.6%) patients had documented Reverse Transcription Polymerase Chain Reaction (RTPCR) reports in favor of COVID-19 and others had clinical features consistent with COVID-19. Only 1% of patient took COVID-vaccination. Of the total 88 patients, 42 (47%) were on oxygen therapy, 72 (81%) had history of blood transfusion, and 48 (54%) were given steroids. Conclusions: No conclusive etiological factor was identified although few recommendations are suggested for prevention, early diagnosis, and prompt management of mucormycosis in hospitalized COVID-19 patients.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
